Trial Profile
The TEEL Study: A Phase I Trial of Tamoxifen With Ribociclib (LEE011) in Adult Patients With Advanced ER+ (HER2 Negative) Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Jan 2022
Price :
$35
*
At a glance
- Drugs Ribociclib (Primary) ; Ribociclib (Primary) ; Goserelin; Tamoxifen
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Adverse reactions
- Acronyms TEEL
- 13 Jan 2022 Status changed from active, no longer recruiting to completed.
- 15 Nov 2021 Planned End Date changed from 1 Dec 2021 to 1 Jan 2022.
- 06 Jul 2021 Planned End Date changed from 1 Jun 2021 to 1 Dec 2021.